ES
12
3
OKE
61
2
ESS
44
5
VRSN
59
4
EMN
40
5
GOOG
77
14
WM
53
2
MA
60
5
STZ
42
2
BLK
46
2
CPB
24
2
SLB
41
2
VMC
41
2
NOV
45
2
LB
16
9
DRI
74
5
NWL
48
4
LOW
42
14
KSS
36
2
CVX
25
14
ES
12
3
OKE
61
2
ESS
44
5
VRSN
59
4
EMN
40
5
GOOG
77
14
WM
53
2
MA
60
5
STZ
42
2
BLK
46
2
CPB
24
2
SLB
41
2
VMC
41
2
NOV
45
2
LB
16
9
DRI
74
5
NWL
48
4
LOW
42
14
KSS
36
2
CVX
25
14
Financhill
Back

ADMA Biologics 10K Form

Buy
60

ADMA
ADMA Biologics

Last Price:
$17.44
Seasonality Move:
2.93%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ADMA News And Ratings

See the #1 stock for the next 7 days that we like better than ADMA

ADMA Financial Statistics

Sales & Book Value

Annual Sales: $258.2M
Cash Flow: $23.9M
Price / Cash Flow: 52.39
Annual Sales: $0.98
Price / Book: 17.74

Profitability

EPS (TTM): 0.28000
Net Income (TTM): $68.1M
Gross Margin: $88.9M
Return on Equity: 39.59%
Return on Assets: 18.97%

ADMA Biologics Earnings Forecast

Key ADMA Biologics Financial Ratios

  • The Gross Profit Margin over the past 14 years for ADMA is 34.44%.
  • The Selling, General & Administrative Expenses for ADMA have been equal to 22.86% of Gross Profit Margin.
  • The Research & Development expenses have been 1.28% of Revenue.
  • The Interest Expense is -88.63% of Operating Income.
  • The Net Earning history of ADMA is -10.94% of Total Revenues.
  • Per Share Earnings over the last 14 years have been positive in 9 years.

ADMA Biologics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ADMA
CUSIP: 000899
Website: admabiologics.com

Debt

Debt-to-Equity Ratio: 0.44
Current Ratio: 7.09
Quick Ratio: 3.05

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 23.41

ADMA Technical Analysis vs Fundamental Analysis

Buy
60
ADMA Biologics (ADMA) is a Buy

Is ADMA Biologics a Buy or a Sell?

  • ADMA Biologics stock is rated a Buy
    The current ADMA Biologics [ADMA] share price is $17.40. The Score for ADMA is 60, which is 20% above its historic median score of 50, and infers lower risk than normal.